Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Shield Therapeutics ( (GB:STX) ) is now available.
Shield Therapeutics has entered into an exclusive license agreement with VITAL-NET, Inc. for the commercialization of ACCRUFeR® in Japan, a significant market due to its high prevalence of iron deficiency. This agreement includes an initial payment to Shield and potential milestone payments, with VITAL-NET covering all development and regulatory costs. The partnership is expected to enhance Shield’s global footprint and provide a new treatment option for iron deficiency in Japan, particularly benefiting women, children, and the elderly.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial stage specialty pharmaceutical company focused on addressing iron deficiency, with or without anemia, through its innovative product ACCRUFeR®/FeRACCRU® (ferric maltol). The company has established various international partnerships to expand its market presence, including collaborations in the U.S., Europe, China, and other regions.
YTD Price Performance: -12.96%
Average Trading Volume: 2,642,839
Technical Sentiment Signal: Strong Buy
Current Market Cap: £24.48M
For a thorough assessment of STX stock, go to TipRanks’ Stock Analysis page.